Results Body weight and biochemical analysis There were no significant differences in body weight among the three groups (Fig
Gomez Perdiguero E, Schulz C, Geissmann F
In 2024, Lemonaid Health launched its own GLP-1 weight-management program, partly inspired by a 23andMe genetic study exploring why these medications work better for some people than others, and why some experience stronger side effects
Competitive Landscape Which are the Leading Players in Oral Non-Peptide GLP-1 Receptor Agonist Market
Eye color is created by a type of pigmentation called melanin
: JAMA Psychiatry study highlights (semaglutide in schizophrenia spectrum disorders): Studied adults with schizophrenia spectrum disorders treated with clozapine or olanzapine, two antipsychotics strongly linked to weight gain and metabolic syndrome Participants were randomized to receive semaglutide (GLP-1 receptor agonist) vs placebo, in addition to usual psychiatric care Significant weight loss was observed in the semaglutide group compared with placebo Improved glycemic control including reductions in HbA1c and fasting glucose, even in early metabolic dysregulation Beneficial effects seen early, suggesting potential for prevention of diabetes rather than late treatment Semaglutide was generally well tolerated, with no worsening of psychotic symptoms Addresses a major unmet need, people with serious mental illness die earlier largely due to cardiometabolic disease Supports the role of GLP-1 receptor agonists as an adjunct treatment to mitigate antipsychotic-induced metabolic harm Bottom line: A promising strategy to reduce weight, diabetes risk, and long-term cardiovascular mortality in patients on high-risk antipsychotics
![Noncovalent Binding between Guanidinium and Anionic Groups: Focus on Biological- and Synthetic-Based Arginine/Guanidinium Interactions with Phosph[on]ate and Sulf[on]ate Residues](https://pubs.acs.org/cms/10.1021/cr040603j/asset/images/medium/cr040603jf1.gif)
